Top

The power of
vascular innovation.

Imagine a readily available, “off the shelf ” bioengineered human acellular vessel (HAV)
that could replace a patients own blood vessel or create a new vascular access
for patients who require dialysis, without requiring cells or tissue from the patient.

Humacyte is making that happen.

What We Do

Groundbreaking
technology

Our unique process, paired with
innovation and continued improvement
and evolution, puts us at the forefront.

Who We Are

Making a
meaningful
impact on
patient care.

In the News

Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium

Science Translational Medicine Publishes Results That Humacyte’s “Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels following Human Implantation”

Humacyte Appoints Dr. Chris Fang as Chief Medical Officer

Humacyte to Present at the 37th Annual J.P. Morgan Healthcare Conference

What We Do

Why Human Accellular Vessels (HAV)?

From lower costs to fewer operations, HAVs may offer critical benefits.

Contact Us

We'd love to
hear from you.




Who We Are

Our path
to success.

With each year, we’ve moved
closer to lifesaving treatments.

Join Our Team

Join our team
and make
a difference.